

The latest, cutting-edge advances in diabetes research, prevention, and care.

Print this Page for Your Records

Close Window

Control/Tracking Number: 2023-A-2216-Diabetes

Activity: Abstract


Current Date/Time: 1/4/2023 2:18:29 PM

4T Study: Early CGM Initiation and Tighter Glucose Targets Improves A1c in Youth with T1D

Author Block: PRIYA PRAHALAD, VICTORIA DING, DESSI P. ZAHARIEVA, ANANTA ADDALA, FRANZISKA K. BISHOP, DAVID SCHEINKER, RAMESH JOHARI, MANISHA DESAI, KOREY K. HOOD, DAVID M. MAAHS, 4T STUDY GROUP, Stanford, CA, Palo Alto, CA

Abstract:

Methods to optimize care after T1D diagnosis are needed. We hypothesized lowering A1c targets to <7% would further lower A1c in the 4T Study in which CGM with asynchronous remote patient monitoring (RPM) is initiated after T1D diagnosis. All youth with newly diagnosed T1D (June 2020-March 2022) were offered CGM and RPM after diagnosis (Study 1, n=133). We compared A1c at 1-year in Study 1 with the 4T Pilot (2018-20) and Historical cohorts (2014-16). We visualized population-based A1c trajectories using locally estimated scatter plot smoothing (Fig) and % meeting A1c targets. Mean A1c at diagnosis was similar in Pilot (12.2%±2.1%) and Study 1 (12.2±2.4%) and higher than the Historical cohort (10.7±2.5%). In Study 1, the median age of diagnosis was 10.8 years, 55% male, 40% non-Hispanic White, and 38% with public insurance. CGM initiation occurred within 30 days of diagnosis in 98.5%. At 3, 6, 9, and 12 months post-diagnosis, the Study 1 cohort had LOESS-based mean A1c differences of 0.16%, 0.24%, 0.31%, and 0.58% lower than the Pilot and 0.04%, 0.60%, 0.83%, and 1.06% lower than the Historical cohort. A1c target <7% was met by 61% of youth in Study 1, 51% in the Pilot and 28% in the Historical cohort. Time <70mg/dl was <2.3%. The 4T program which emphasizes early CGM initiation, RPM, tighter glucose targets, and consistent team messaging was associated with lower A1c. These data support implementation of the 4T program in youth with T1D.



Category (Complete): 15-B Pediatrics—Type 1 Diabetes Presentation Preference (Complete): Oral Preferred Financial Support (Complete):

* ADA Support: No

Supported by: : This work was supported in part by the National Institutes of Health P30DK116074 via the Stanford Diabetes Research Center and R18DK122422 to D.M.M. CGM supplies for the first month (transmitter, 3 sensors, and receiver per patient) were donated by Dexcom. Funding for iOS devices and some CGM supplies was provided by a grant through the Lucile Packard Children's Hospital Auxiliaries Endowment. This research was supported by the Stanford Maternal and Child Health Research Institute under the Transdisciplinary Initiatives Program.

Payment (Complete): Your credit card order has been processed on Wednesday 4 January 2023 at 2:02 PM.

Status: Complete

American Diabetes Association 2451 Crystal Drive, Suite 900 Arlington, VA 22202

For questions regarding the abstract submission process, email abstracts@diabetes.org

For Technical Support please contact cOASIS Helpdesk at diabetes@support.ctimeetingtech.com or 217-398-1792 between the hours of 7:00 AM and 6:00 PM (CT) Monday through Friday.

Powered by $\underline{\text{cOASIS}}$, The Online Abstract Submission and Invitation System $^{\text{SM}}$ © 1996 - 2023 CTI Meeting Technology. All rights reserved. Privacy Policy.